Morgan Stanley’s Matinas BioPharma MTNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $211 | Hold |
23
| – | – | ﹤0.01% | 7840 |
|
|
2026
Q1 | $172 | Sell |
23
-14
| -38% | -$131 | ﹤0.01% | 7708 |
|
|
2025
Q4 | $328 | Hold |
37
| – | – | ﹤0.01% | 7573 |
|
|
2025
Q3 | $1.06K | Buy |
37
+27
| +270% | +$582 | ﹤0.01% | 7386 |
|
|
2025
Q2 | $128 | Hold |
10
| – | – | ﹤0.01% | 7620 |
|
|
2025
Q1 | $75 | Hold |
10
| – | – | ﹤0.01% | 7622 |
|
|
2024
Q4 | $73 | Sell |
10
-25
| -71% | -$571 | ﹤0.01% | 7518 |
|
|
2024
Q3 | $1.84K | Sell |
35
-26
| -43% | -$2.48K | ﹤0.01% | 7145 |
|
|
2024
Q2 | $7.28K | Sell |
61
-2
| -3% | -$272 | ﹤0.01% | 6762 |
|
|
2024
Q1 | $12.9K | Buy |
63
+26
| +70% | +$4.63K | ﹤0.01% | 6607 |
|
|
2023
Q4 | $5.95K | Sell |
37
-3
| -8% | -$508 | ﹤0.01% | 6793 |
|
|
2023
Q3 | $3.9K | Hold |
40
| – | – | ﹤0.01% | 6972 |
|
|
2023
Q2 | $10.8K | Sell |
40
-10
| -20% | -$3.5K | ﹤0.01% | 6790 |
|
|
2023
Q1 | $17.5K | Sell |
50
-2
| -4% | -$758 | ﹤0.01% | 6674 |
|
|
2022
Q4 | $19.5K | Buy |
52
+25
| +93% | +$12.5K | ﹤0.01% | 6704 |
|
|
2022
Q3 | $13K | Sell |
27
-26
| -49% | -$15.3K | ﹤0.01% | 6984 |
|
|
2022
Q2 | $31K | Sell |
53
-18
| -25% | -$10.3K | ﹤0.01% | 6822 |
|
|
2022
Q1 | $43K | Sell |
71
-24
| -25% | -$13.2K | ﹤0.01% | 6780 |
|
|
2021
Q4 | $72K | Buy |
95
+22
| +30% | +$17.6K | ﹤0.01% | 6624 |
|
|
2021
Q3 | $71K | Buy |
73
+3
| +4% | +$1.94K | ﹤0.01% | 6552 |
|
|
2021
Q2 | $41K | Buy |
70
+17
| +32% | +$11K | ﹤0.01% | 6748 |
|
|
2021
Q1 | $42K | Buy |
53
+1
| +2% | +$1.01K | ﹤0.01% | 6429 |
|
|
2020
Q4 | $54K | Buy |
52
+12
| +30% | +$8.34K | ﹤0.01% | 6141 |
|
|
2020
Q3 | $23K | Buy |
40
+30
| +300% | +$17.9K | ﹤0.01% | 6008 |
|
|
2020
Q2 | $6K | Sell |
10
-943
| -99% | -$542K | ﹤0.01% | 6276 |
|
|
2020
Q1 | $429K | Buy |
953
+930
| +4,043% | +$842K | ﹤0.01% | 4464 |
|
|
2019
Q4 | $39K | Buy |
+23
| New | +$20K | ﹤0.01% | 5929 |
|
|
2019
Q3 | – | Sell |
-1
| Closed | -$1K | – | 6705 |
|
|
2019
Q2 | $1K | Hold |
1
| – | – | ﹤0.01% | 6554 |
|
|
2019
Q1 | $1K | Sell |
1
-2
| -67% | -$1.62K | ﹤0.01% | 6523 |
|
|
2018
Q4 | $2K | Hold |
3
| – | – | ﹤0.01% | 6420 |
|
|
2018
Q3 | $2K | Sell |
3
-425
| -99% | -$137K | ﹤0.01% | 6579 |
|
|
2018
Q2 | $139K | Buy |
428
+225
| +111% | +$97.5K | ﹤0.01% | 5659 |
|
|
2018
Q1 | $116K | Buy |
203
+26
| +15% | +$20.6K | ﹤0.01% | 5661 |
|
|
2017
Q4 | $154K | Buy |
177
+32
| +22% | +$30.9K | ﹤0.01% | 5502 |
|
|
2017
Q3 | $143K | Buy |
145
+78
| +116% | +$78.1K | ﹤0.01% | 5474 |
|
|
2017
Q2 | $85K | Sell |
67
-77
| -53% | -$155K | ﹤0.01% | 5694 |
|
|
2017
Q1 | $300K | Buy |
+144
| New | +$352K | ﹤0.01% | 5116 |
|
Other funds holding MTNB
HIW
SIG
Morgan Stanley's MTNB Position: Q2 2026 in Review
Morgan Stanley held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 23 shares worth $211. The position accounts for ﹤0.01% of the portfolio, ranked #7840.
Morgan Stanley first reported a position in MTNB in Q1 2017 and has held it in 37 quarters since. The position peaked at $429K in Q1 2020. 23 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.
- Morgan Stanley held 23 shares of Matinas BioPharma worth $211 as of Q2 2026.
- Morgan Stanley left its Matinas BioPharma share count unchanged in Q2 2026.
- Matinas BioPharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7840 holding.
- Morgan Stanley first reported a position in Matinas BioPharma in Q1 2017 and has held it in 37 quarters since.
- Morgan Stanley's Matinas BioPharma position peaked at $429K in Q1 2020.
- 23 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.